International Staging System (ISS)
Inputs at diagnosis. Units: β2-microglobulin mg/L, albumin g/dL.
Criteria
Stage I: β2M < 3.5 and albumin ≥ 3.5. Stage III: β2M ≥ 5.5. Stage II: all others.
Revised ISS (R-ISS)
Criteria
Stage I: ISS I, no high-risk cytogenetics, normal LDH. Stage III: ISS III with either high-risk cytogenetics or high LDH. Stage II: all others.
R2-ISS (Second Revision)
Additive points, then group I to IV.
Scoring
Points: ISS II = 1, ISS III = 1.5, del(17p) = 1, t(4;14) = 1, high LDH = 1, 1q+ = 0.5. Totals map to groups: 0 = I, 0.5 to 1 = II, 1.5 to 2.5 = III, 3 to 5 = IV.
mSMART Cytogenetic Risk
Select abnormalities present by FISH or sequencing.
Notes
mSMART groups as High, Intermediate, or Standard based on common lesions. Therapeutic implications evolve, interpret with clinical context.
IMWG Frailty Score
Use at baseline to guide intensity. Scored from age, Charlson Comorbidity Index, Katz ADL, and Lawton IADL.
Scoring
Points: Age 76 to 80 = 1, age greater than 80 = 2, CCI ≥ 2 = 1, ADL ≤ 4 = 1, IADL ≤ 5 = 1. Sum: 0 fit, 1 intermediate fitness, ≥ 2 frail.
Smoldering Myeloma 20/2/20 Model
Estimate 2 year progression risk.
Criteria
Risk factors: M protein ≥ 2 g/dL, FLC ratio ≥ 20, marrow plasma cells ≥ 20 percent. 0, 1, or 2 to 3 factors correspond to low, intermediate, or high risk of progression at 2 years.
HCT-CI, Transplant Comorbidity Index
Check all comorbidities present before transplant. Scoring per Sorror et al., Blood 2005. Optional: add 1 point if age ≥ 40 to compute the composite HCT-CI plus age.
Scoring and risk groups
Item weights: 1 point, arrhythmia, cardiac, IBD, diabetes, cerebrovascular disease, psychiatric disturbance, hepatic mild, obesity, infection. 2 points, rheumatologic, peptic ulcer, renal moderate or severe, pulmonary moderate. 3 points, prior solid tumor, heart valve disease, pulmonary severe, hepatic moderate or severe. Total HCT-CI risk groups: 0 low, 1 to 2 intermediate, ≥ 3 high. Composite HCT-CI plus age adds 1 point for age ≥ 40.